Latest Breaking News On - Light therapeutics - Page 1 : comparemela.com

MAPLIGHT THERAPEUTICS APPOINTS MARIA WALKER TO BOARD OF DIRECTORS

MAPLIGHT THERAPEUTICS APPOINTS MARIA WALKER TO BOARD OF DIRECTORS
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

San-diego
California
United-states
Boston
Massachusetts
Maria-walker
Christopher-kroeger
Montes-archimedes-acquisition-corp
University-of-california
Audit-committee
Light-therapeutics
Chief-executive-officer

MAPLIGHT THERAPEUTICS ANNOUNCES INITIATION OF PHASE 1 CLINICAL TRIAL FOR ML-007/PAC, UNDER DEVELOPMENT FOR SCHIZOPHRENIA AND ALZHEIMER's DISEASE PSYCH...

MAPLIGHT THERAPEUTICS ANNOUNCES INITIATION OF PHASE 1 CLINICAL TRIAL FOR ML-007/PAC, UNDER DEVELOPMENT FOR SCHIZOPHRENIA AND ALZHEIMER's DISEASE PSYCH...
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

Boston
Massachusetts
United-states
Christopher-kroeger
John-kane
Light-therapeutics
Chief-executive-officer
Barbara-zucker-school

MAPLIGHT THERAPEUTICS ANNOUNCES INITIATION OF PHASE 1 CLINICAL TRIAL FOR ML-007/PAC, UNDER DEVELOPMENT FOR SCHIZOPHRENIA AND ALZHEIMER'S DISEASE PSYCHOSIS

MAPLIGHT THERAPEUTICS ANNOUNCES INITIATION OF PHASE 1 CLINICAL TRIAL FOR ML-007/PAC, UNDER DEVELOPMENT FOR SCHIZOPHRENIA AND ALZHEIMER'S DISEASE PSYCHOSIS
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Boston
Massachusetts
United-states
John-kane
Christopher-kroeger
Charmaine-lykins
Maplight-therapeutics-inc
Maplight-therapeutics
Chief-executive-officer
Barbara-zucker-school
Chief-commercial-officer
Light-therapeutics

MAPLIGHT THERAPEUTICS ANNOUNCES COMPLETION OF PHASE 1 CLINICAL TRIAL FOR NOVEL M1/M4 MUSCARINIC AGONIST IN DEVELOPMENT FOR SCHIZOPHRENIA AND ALZHEIMER'S DISEASE PSYCHOSIS

MAPLIGHT THERAPEUTICS ANNOUNCES COMPLETION OF PHASE 1 CLINICAL TRIAL FOR NOVEL M1/M4 MUSCARINIC AGONIST IN DEVELOPMENT FOR SCHIZOPHRENIA AND ALZHEIMER'S DISEASE PSYCHOSIS
lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.

Charmaine-lykins
Christopher-kroeger
Maplight-therapeutics-inc
Light-therapeutics
Chief-executive-officer
Maplight-chief-medical-officer
Erin-pennock-foff
Chief-commercial-officer

MapLight Therapeutics, Inc.: MapLight Therapeutics Closes $225 Million Series C Funding Round to Advance Pipeline of Central Nervous System Therapeutics

MapLight Therapeutics, Inc.: MapLight Therapeutics Closes $225 Million Series C Funding Round to Advance Pipeline of Central Nervous System Therapeutics
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Ihre-chancen
Novo-nordisk
Christopher-kroeger
Indiens-wirtschaft
Charmaine-lykins
Jim-trenkle
Novo-nordisk-foundation
Novo-holdings
Cowen-healthcare-investments
Light-therapeutics
Central-nervous-system
Chief-executive-officer